How Iron Absorption Shifts: Heme vs Nonheme

Iron enters the human diet in two chemically distinct forms: heme iron, which is bound inside a porphyrin ring structure derived from hemoglobin and myoglobin in animal tissue, and nonheme iron, which arrives as free ionic iron from plant foods, fortified products, and most dietary supplements. The distinction is not cosmetic — the two forms are recognized by entirely different transport proteins at the intestinal wall, follow separate routes into the enterocyte, and are regulated by different feedback signals.

This article covers the mechanics of that split: how each form is recognized, what cellular machinery handles the transfer, which dietary compounds accelerate or inhibit absorption, and what a supplement label can and cannot convey about how much iron will actually reach the bloodstream.

The Two Pathways Iron Takes Into the Enterocyte

Heme iron enters the absorptive cells of the duodenum and upper jejunum largely intact as a metalloporphyrin complex. A membrane-associated heme carrier protein transports the entire porphyrin ring across the brush-border membrane. Once inside the enterocyte, a heme oxygenase enzyme cleaves the ring and releases ferrous iron (Fe²⁺) into the cytoplasm. Because the porphyrin ring shields the iron from luminal chemistry during transit, heme absorption is relatively insensitive to most inhibitors present in the gut at the same time.

Nonheme iron, by contrast, must be reduced to the ferrous (Fe²⁺) state before it can be transported. Dietary iron from plant sources and supplements typically arrives as ferric iron (Fe³⁺). A brush-border enzyme called duodenal cytochrome b (Dcytb) reduces Fe³⁺ to Fe²⁺ at the apical surface of the enterocyte. The divalent metal transporter 1 (DMT1) then carries the Fe²⁺ ion across the membrane into the cell. This reduction step is rate-limiting and is the point at which vitamin C (ascorbic acid) exerts its well-documented facilitating effect — ascorbic acid chemically reduces Fe³⁺ to Fe²⁺ in the lumen, increasing the substrate available for DMT1.

Inside the enterocyte, iron from both pathways converges. It is either stored temporarily as ferritin — an intracellular storage protein — or transferred across the basolateral membrane into the portal circulation. That basolateral transfer is performed by a protein called ferroportin, the only known cellular iron export channel. Ferroportin activity is regulated by hepcidin, a liver-derived peptide hormone that is the master regulator of systemic iron balance. When body iron stores are high, hepcidin levels rise, ferroportin is internalized and degraded, and iron export from the enterocyte slows. When stores are low, hepcidin falls and ferroportin activity increases. This feedback loop operates on both heme and nonheme pathways equally, even though the entry routes differ.

Once in the bloodstream, iron binds to transferrin, a plasma carrier protein, and is delivered to tissues. The liver, bone marrow, and spleen are the principal destinations. Red blood cell precursors in the bone marrow are the largest consumers, incorporating iron into hemoglobin during erythropoiesis.

The Proteins, Compounds, and Organs That Govern Iron Transit

Duodenal cytochrome b (Dcytb): A ferrireductase expressed on the apical surface of duodenal enterocytes. It converts luminal Fe³⁺ to the Fe²⁺ form that DMT1 can transport. Its expression is upregulated when body iron stores fall.

Divalent metal transporter 1 (DMT1): The primary apical transporter for nonheme iron. It is proton-coupled, meaning it functions most efficiently in the acidic microenvironment near the brush border. Reduced gastric acid output — from age, medication, or surgical alteration — can therefore compromise nonheme absorption by reducing the local proton gradient that drives DMT1.

Heme carrier protein / HCP1: Transports intact heme across the apical membrane. Its expression is also upregulated by iron deficiency, though the molecular regulation of heme uptake is less fully characterized than that of the nonheme pathway.

Heme oxygenase-1 (HO-1): Cleaves the porphyrin ring inside the enterocyte, liberating Fe²⁺ and carbon monoxide as byproducts. This step is necessary before heme-derived iron can enter the shared cytoplasmic pool.

Ferritin: An intracellular storage protein that sequesters iron within the enterocyte. Iron held in ferritin is lost when the enterocyte is shed at the end of its roughly three-day lifespan, representing a regulated loss mechanism that prevents excess iron from entering the bloodstream.

Ferroportin: The sole known basolateral iron exporter. Present in enterocytes, macrophages, and hepatocytes. Its surface expression is the primary target of hepcidin-mediated regulation.

Hepcidin: A 25-amino-acid peptide produced by the liver. It binds ferroportin directly, triggering its internalization. Hepcidin synthesis is increased by iron loading, inflammation, and certain hormones, and decreased by iron deficiency and increased erythropoietic demand. Because inflammation raises hepcidin independently of iron stores, absorption can be suppressed even when body iron is low — a biochemical feature relevant to interpreting iron status in the context of chronic illness.

Transferrin: The plasma glycoprotein that carries iron in the circulation. Each transferrin molecule can bind two Fe³⁺ ions. Transferrin saturation — the percentage of transferrin binding sites occupied — is one of several laboratory markers used clinically to assess iron status.

The duodenum and upper jejunum: The anatomical site where the vast majority of dietary iron absorption occurs. The acidic environment created by gastric acid emptying into this segment is critical for nonheme iron solubility and DMT1 function. This is also why bioavailability measurements for iron supplements — much like third-party testing for other nutrients — depend heavily on the conditions under which measurement is performed.

Where Iron Absorption Breaks Down or Produces Unexpected Results

Phytates and polyphenols sharply inhibit nonheme absorption. Phytic acid, found in legumes, whole grains, and seeds, binds nonheme iron in the intestinal lumen to form insoluble complexes that DMT1 cannot transport. Polyphenols in tea, coffee, and red wine form similar complexes. Because heme iron enters as an intact metalloporphyrin, it is largely protected from these luminal interactions — a mechanistic reason why bioavailability estimates for heme iron (typically 15–35%) tend to exceed those for nonheme iron (2–20%) under mixed dietary conditions.

Calcium competes with nonheme iron at DMT1. Calcium is also a substrate for DMT1, and high luminal calcium concentrations reduce nonheme iron transport. This interaction is specific to the intestinal lumen and does not appear to affect long-term iron status significantly in most populations, but it is detectable in short-term absorption studies.

Gastric acid dependency creates a vulnerability in nonheme absorption. Proton pump inhibitors (PPIs), H2-receptor antagonists, and conditions that reduce stomach acid output lower the acidity of the duodenal environment. This reduces Fe³⁺ solubility and weakens the proton gradient that drives DMT1, resulting in measurably lower nonheme iron absorption. Heme iron absorption is comparatively unaffected.

Inflammation suppresses absorption independent of stores. Hepcidin is an acute-phase reactant. Infections, inflammatory conditions, and even strenuous physical stress can raise hepcidin levels within hours, reducing ferroportin expression and slowing iron export from enterocytes. The result is that measured serum iron can fall and absorption appears impaired even when dietary intake is adequate — a pattern that can complicate interpretation of iron status markers. This regulatory complexity is worth noting when comparing iron's absorption behavior to nutrients whose uptake is less hormonally regulated, such as the amino acids in a complete protein.

Supplement form affects luminal chemistry. Ferrous salts (ferrous sulfate, ferrous gluconate, ferrous fumarate) are more soluble at intestinal pH than ferric salts and are more readily reduced by Dcytb. Ferric forms require more reduction before DMT1 can act on them. Chelated forms, such as iron bisglycinate, may be absorbed through a partially distinct pathway and show different inhibitor sensitivity in some studies, though the evidence base is still developing. The variation in absorption across supplement forms illustrates a general principle in supplement biochemistry: the chemical matrix surrounding an active compound shapes its bioavailability, a point that also arises when examining how curcumin's absorption is measured across different formulations.

Individual absorption is highly variable. Iron absorption is not fixed at a population average. It varies by iron status (low stores upregulate DMT1 and Dcytb expression), age, sex, pregnancy status, erythropoietic rate, and genetic polymorphisms in transport proteins. A single bioavailability figure on a supplement label reflects an average derived from study conditions that may not match any individual's actual physiology.

What an Iron Supplement Label Shows — and What It Cannot

A supplement facts panel lists elemental iron content in milligrams and expresses it as a percentage of the Daily Value (DV), which is set by the FDA at 18 mg for adults following a reference diet. The elemental iron figure reflects what is present in the tablet or capsule before ingestion — it says nothing about the fraction that will cross the intestinal wall and enter the bloodstream.

The label identifies the iron compound used (e.g., ferrous sulfate, ferric pyrophosphate, iron bisglycinate), which is the only label element that gives any indirect signal about likely absorption behavior, since different salts have different solubility profiles. However, no label is required to state a bioavailability percentage, and the FDA does not approve dietary supplements before sale or verify label claims about absorption efficiency. Under the Dietary Supplement Health and Education Act (DSHEA), manufacturers are responsible for ensuring their products are safe and that any claims made are truthful and not misleading, but pre-market bioavailability testing is not mandated.

Third-party certifications — from organizations that test for identity, purity, and label accuracy — can confirm that a product contains the stated amount of elemental iron and is free from specified contaminants. They do not and cannot certify how much of that iron will be absorbed by any individual consumer. A certification seal is a statement about what is in the container, not about what will reach the portal circulation.

No structure/function claim on an iron supplement label — such as "supports healthy red blood cell production" — constitutes evidence of clinical efficacy or absorption adequacy. Such claims must be accompanied by the FDA-required disclaimer that the statement has not been evaluated by the FDA and that the product is not intended to diagnose, treat, cure, or prevent any disease.

The heme and nonheme distinction illustrates a broader principle in mineral nutrition: chemical form and luminal environment are not secondary details but primary determinants of how much of a listed nutrient actually enters the body. The milligram figure on a label marks a starting point in a regulated, context-dependent process, not an endpoint.

Note: This explains how supplements work. This statement has not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease, and it is not a substitute for advice from a physician, pharmacist, or registered dietitian.